Cell Isolation Market - Different Growth Strategies Adopted by Leading Companies

Overview of This Study:

This study involved four major activities in estimating the current size of the cell isolation market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research.

Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate segments and subsegments' market size.

Major Growth Driving Factors:

Growth in this market is largely driven by factors such as the increasing government funding for cell-based research, the increasing number of patients suffering from cancer and infectious diseases, technological advancements, and the growing focus on personalized medicine. On the other hand, ethical issues related to embryonic stem cell isolation and the high cost of cell-based research are expected to limit market growth to a certain extent in the coming years.

Find More Details – Download PDF Brochure@

Global Leading Companies:

The major players in this market are Thermo Fisher Scientific, Inc. (US), Becton, Dickinson and Company Limited (US), Beckman Coulter Inc. (US).Merck KGaA (Germany), Terumo BCT (Japan), GE Healthcare (US), Bio- Rad Laboratories Inc. (US), Corning Inc. (US), Roche Diagnostics (Switzerland, Alfa Laval (Sweden), Miltenyl Biotech (Germany), pluriSelect Life Science (Germany), STEMCELL Technologies Inc. (Canada), Akadeum Life Sciences, Inc (US), Bio- Techne (US), Bio Legend (US) and Invent Biotechnologies (US).

Thermo Fisher Scientific accounted for the largest share of the cell isolation market in 2019. The company offers an exhaustive product portfolio comprising various cell isolation products, such as reagents and kits, media, magnetic beads, and centrifuges. The company pursues both organic as well as inorganic growth strategies to enhance its market position. To maintain its leading position and enhance its market share, the company is customer-oriented and maintains a strong relationship with its customers.

In 2019, Becton, Dickinson and Company accounted for the second-largest share of the cell isolation market. It operates in the cell isolation market through its BD Biosciences segment.The company has an extensive product portfolio, ranging from instruments to accessories. It also has a strong distribution network for flow cytometers, reagents, kits, and magnetic separators. The company has been focusing on technological advancements as its key growth strategy, to maintain its position in the market.

Beckman Coulter, Inc. was the third-largest player in the cell isolation market, in 2019. To sustain its leadership position in the market, the company focuses on continuous innovation and product development. For instance, the company launched its ClearLLab 10C System for the clinical flow cytometry lab in 2019. The new system includes the first 10-color CE-IVD panels of immunophenotyping reagents for both lymphoid and myeloid lineages.

Recent Developments by Leading Companies:

# In May 2019, Thermo Fisher Scientific acquired Brammer Bio with the aim to expand capabilities to support the high growth gene and cell therapy market.

# In October 2018, Merck opened its M Lab Collaboration Center in Sao Paulo

# In May 2019, Beckman Coulter launched ClearLLab 10C System

Request to Get the Customized Information@

Geographical Growth Scenario:

North America is the largest regional market for cell isolation market

The cell isolation market is segmented into four regions, namely, North America, Europe, Asia Pacific and Rest of the world. In 2019, North America accounted for the largest share of the cell isolation market. The large share of North America can be attributed to technological advancements, growth in the biotechnology and pharmaceutical industries, increasing prevalence of chronic and infectious diseases, and higher investments in cell-based research in the region.